<DOC>
	<DOCNO>NCT01732861</DOCNO>
	<brief_summary>This dose find study use 3 + 3 dose escalation expansion design determine Not Tolerated Dose ( NTD ) , Optimal Biological Effect Dose ( OBE ) / Maximum Tolerated Dose ( MTD ) . These data use establish Recommended Phase 2 Dose ( RP2D ) combination CC-292 lenalidomide subject Chronic Lymphocytic Leukemia ( CLL ) .</brief_summary>
	<brief_title>Safety Study CC-292 Lenalidomide Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma</brief_title>
	<detailed_description>This dose find study use 3 + 3 dose escalation expansion design establish recommend Phase 2 dose . The start dose CC-292 375 mg twice daily Lenalidomide 10 mg daily . After review data dose limit toxicity ( DLTs ) , second dose level enrol . Doses second cohort CC-292 500 mg twice daily lenalidomide 10 mg daily . Additional dos lenalidomide combination CC-292 may evaluate accurately determine maximum tolerate dose . Once maximum tolerate dose and/or optimal biologic effect ascertain , expansion cohort 24 subject may enrol .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Male female subject 18 year age old time signing informed consent document ( ICD ) . Body weight least 50 kg . Must document diagnosis CLL/SLL ( International Workshop Chronic Lymphocytic Leukemia IWCLL Guidelines Hallek 2008 ) investigator assessment . Have fail least 1 previous treatment CLL/SLL , relapse and/or refractory disease follow last prior treatment define CLL/SLL achieve least partial response ( PR ) therapy progress within 6 month treatment . Eastern Cooperative Oncology Group performance status ( ECOG PS ) 2 less . Life expectancy least 3 month time sign ICD . Females childbearing potential ( FCBP ) must negative medically supervised pregnancy test prior start study therapy agree ongoing pregnancy test end study therapy ; commit continue abstinence heterosexual intercourse agree use , comply two effective method contraception without interruption , 28 day prior start study drug , study therapy , 28 day discontinuation study therapy . Male subject must agree use latex condom sexual contact FCBP even vasectomy , throughout study drug therapy dose interruption , 28 day end study therapy ; agree donate semen sperm study drug therapy 28 day end study drug therapy . All subject must understand lenalidomide could potential teratogenic risk , agree abstain donate blood take lenalidomide therapy follow discontinuation study drug therapy ; echocardiogram ( ECG ) multigated acquisition ( MUGA ) scan heart demonstrate leave ventricular ejection fraction ( LVEF ) least 50 % institution 's low limit normal ; recovered adverse , toxic effect prior therapy equal less 1 ( National Cancer Institute [ NCI ] Common Terminology Criteria Adverse Events [ CTCAE ] version 4.03 except alopecia peripheral neuropathy . Any significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study . Autologous stem cell transplant within 3 month prior time signature ICD Informed Consent Document . Uncontrolled intercurrent illness include , limited ongoing active infection require parenteral antibiotic ; uncontrolled diabetes mellitus ; chronic symptomatic congestive heart failure ; unstable angina pectoris , angioplasty , stenting , myocardial infarction within 6 month prior time signature ICD ; clinically significant cardiac arrhythmia symptomatic require treatment , asymptomatic sustain ventricular tachycardia . Subjects control atrial fibrillation asymptomatic eligible . Pregnant lactating female . Prior history malignancy , unless subject free disease 5 year prior time signature ICD . Exceptions 5 year time limit include history basal cell carcinoma skin ; squamous cell carcinoma skin ; carcinoma situ cervix ; carcinoma situ breast ; carcinoma situ bladder ; incidental histologic find prostate cancer ( Tumor/Nodes/Metastasis [ TNM ] stage T1a T1b ) . Known seropositivity history active viral infection human immunodeficiency virus ( HIV ) . Known seropositivity hepatitis C virus ( HCV ) ; hepatitis B virus ( HBV ) . Subjects high risk thromboembolic event willing/able take venous thromboembolic event ( VTE ) prophylaxis . Any following laboratory abnormality : 1 . Absolute Neutrophil Count ( ANC ) ≤ 1,000 cells/mm3 ( 1.0 x 109/L ) 2 . Platelet count ≤ 50,000/mm3 ( 50 x 109/L ) unless secondary bone marrow involvement recent bone marrow aspiration bone marrow biopsy 3 . Serum Aspartate Transaminase/Serum GlutamicOxaloacetic Transaminase ( AST/SGOT ) Alanine Transaminase/Serum GlutamicPyruvic Transaminase ( ALT/SGPT ) &gt; 3.0 x upper limit normal ( ULN ) &gt; 5.0 x ULN case document liver involvement 4 . Serum bilirubin &gt; 1.5 x ULN &gt; 3.0 x ULN case Gilbert 's Syndrome document liver involvement lymphoma ; 5 . Calculated creatinine clearance use CockcroftGault formula ( Cockcroft,1976 ) 6 . Corrected QT interval ( QTc ) prolongation ( define QTc &gt; 450 msec male &gt; 470 msec female [ Fridericia 's correction ] ) clinically significant ECG abnormality assess investigator . Chemotherapy , radiotherapy , investigational anticancer therapy major surgery within 28 day Day 1 dosing . Use systemic corticosteroid dos great prednisone equivalent 20 mg/day within 3 week prior study drug dosing . Concomitant use medicine know cause QT prolongation torsades de pointes . Chronic use H2 antagonists proton pump inhibitor use within 7 day first dose . Gastrointestinal abnormality include inability take oral medication , require intravenous alimentation , prior surgical procedure affect absorption . Prior treatment Btk ( Bruton 's tyrosine kinase ) inhibitor . Any live vaccination within 3 week first dose . History hypersensitivity immunomodulatory drug ( IMiDs ) ( eg , lenalidomide , thalidomide , pomalidomide ) . Disease transformation ( ie , Richter 's Syndrome [ lymphomas ] prolymphocytic leukemia ) . Patients uncontrolled hyper hypothyroidism .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Small Lymphocytic Leukemia</keyword>
</DOC>